Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
2,650
Views
6
CrossRef citations to date
0
Altmetric
Author’s View

Expand to shield: IL-15 and in situ lymphocytic proliferation

Gabriela Bindeaa Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;b Equipe Labellisée Ligue Contre le Cancer, Paris, France;c Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FranceView further author information
,
Bernhard Mlecnika Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;b Equipe Labellisée Ligue Contre le Cancer, Paris, France;c Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, France;d Inovarion, Paris, FranceView further author information
&
Jérôme Galona Laboratory of Integrative Cancer Immunology, INSERM, Paris, France;b Equipe Labellisée Ligue Contre le Cancer, Paris, France;c Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, FranceCorrespondence[email protected]
View further author information
Article: 1886726 | Received 03 Feb 2021, Accepted 03 Feb 2021, Published online: 12 Feb 2021

References

  • Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52:55–3. doi:10.1016/j.immuni.2019.12.018. PMID: 31940273.
  • Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020. doi:10.1038/s41568-020-0285-7. PMID: 32753728.
  • Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33:335–340. doi:10.1007/s00281-011-0264-x. PMID: 21461991.
  • Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med. 2016;14:273. doi:10.1186/s12967-016-1029-z. PMID: 27650038.
  • Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pages F. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28:373–382. doi:10.1093/intimm/dxw021. PMID: 27121213.
  • Mlecnik B, Bifulco C, Bindea G, Marliot F, Lugli A, Lee JJ, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, et al. Multicenter international society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer. J Clin Oncol. 2020;38:JCO1903205. doi:10.1200/jco.19.03205. PMID: 32897827.
  • Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008;84:981–987. doi:10.1189/jlb.1107773. PMID: 18559950; [pii] 10.1189/jlb.1107773.
  • Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–218. doi:10.1038/s41573-018-0007-y. PMID: 30610226.
  • Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014;6:228ra237. doi:10.1126/scitranslmed.3007240. PMID: 24648340.
  • Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology. 2010;138:1429–1440. doi:10.1053/j.gastro.2009.10.057. PMID: 19909745.
  • Bergamaschi C, Pandit H, Nagy BA, Stellas D, Jensen SM, Bear J, Cam M, Valentin A, Fox BA, Felber BK, et al. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10. J Immunother Cancer. 2020;8:e000599. doi:10.1136/jitc-2020-000599. PMID: 32461349.
  • Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, et al. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology. 2016;5:e1115942. doi:10.1080/2162402x.2015.1115942. PMID: 27057468.
  • Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines in cancer therapy. Oncoimmunology. 2014;3:e29030. doi:10.4161/onci.29030. PMID: 25083328.
  • Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: immunostimulatory cytokines. Oncoimmunology. 2013;2:e24850. doi:10.4161/onci.24850. PMID: 24073369.
  • Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial watch: immunostimulatory cytokines. Oncoimmunology. 2012;1:493–506. doi:10.4161/onci.20459. PMID: 22754768.
  • Waldmann TA, Dubois S, Miljkovic MD, Conlon KC. IL-15 in the combination immunotherapy of cancer. Front Immunol. 2020;11:868. doi:10.3389/fimmu.2020.00868. PMID: 32508818.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.